Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + rituximab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BR is a standard-of-care chemoimmunotherapy regimen comprising bendamustine, a bifunctional alkylating agent, and rituximab, a chimeric monoclonal antibody targeting the CD20 antigen. This combination is widely utilized in the treatment of various indolent B-cell non-Hodgkin lymphomas, including follicular lymphoma (FL) and mantle cell lymphoma (MCL), as well as chronic lymphocytic leukemia (CLL). Bendamustine exerts its cytotoxic effect by forming intra-strand and inter-strand DNA cross-links, which interfere with DNA replication and transcription, leading to cell cycle arrest and apoptosis. Rituximab binds to CD20 on the surface of B-lymphocytes, mediating cell lysis through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and the induction of direct apoptosis. In clinical trials such as SOUNDTRACK-F1, BR serves as a benchmark comparator for evaluating the efficacy of novel therapies, such as surovatamig (AZD0486), in previously untreated follicular lymphoma.
- Other names
- Bendamustine-RituximabRituximab-Bendamustine
02
Targets
Beyond the preview
Go deeper on bendamustine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + rituximab.